BioNtech SE on Muck Rack

BioNtech SE

As seen in: Yahoo News New Zealand, Oxford Academic, Yahoo Finance, Yahoo Finance Singapore, Yahoo Finance UK, Associated Press: Press Releases, Frontiers, International Business Times (U.S.), Investing.com, The Boston Globe and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with BioNtech

Contact BioNtech, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Tumor-naïve ctDNA detection with deep learning-enhanced error suppression for sensitive mutation calling

|
By Jos de, Johannes Gutenberg Mainz, BioNtech SE
| TechTrends
Background Circulating tumor DNA (ctDNA) detection offers minimally invasive monitoring of cancer from blood samples. While tumor-informed approaches are sensitive, their clinical application is limited by cost, tissue availability, and turnaround time. In contrast, tumor-naïve assays offer faster turnaround times and broader applicability, but often sacrifice sensitivity.
Open in Who Shared Issue with article?

Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

|
By BioNtech SE
| eastmnweeklynews.com
First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 expression levels and subtypes, highlighting its potential to set a new standard of care Pumitamig plus chemotherapy showed robust and consistent antitumor activity in first-line non-small cell lung cancer at both evaluated dose levels, with higher confirmed objective response rates at the lower...
Open in Who Shared View Duplicates (326) Issue with article?
See all 4,679 licensed articles (4,680 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified